Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc has bolstered its financial and clinical position by completing an $8 million financing round and advancing its EB103 therapy into the Phase II portion of its ongoing study, which indicates strong investor confidence and progress in its clinical pipeline. The favorable safety profile and positive early results from the EB103 cohort encourage a promising outlook, especially with potential advancements in the EB104 dual-target program for B-cell malignancies and autoimmune conditions. Furthermore, Estrella’s Artemis Technology platform represents a novel approach in CAR-T therapy, unlocking new market opportunities and the potential to treat solid tumors, which could significantly enhance its market position in the immunotherapy landscape.

Bears say

Estrella Immunopharma faces a negative outlook primarily due to the potential for future stock dilution, which raises concerns among investors about the company's capital management and financial health. The recent revision of the target price from $16.0 to $8.0 reflects a conservative approach by management in light of ongoing strategic discussions that may impact partnership opportunities and pipeline prioritization. Furthermore, the lack of detailed financial metrics in the provided excerpts underlines the uncertainties surrounding the company's revenue forecasts from their CD19 and CD22-targeted therapies, implying a challenging environment for achieving growth and profitability.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.